Company intelligence / Profile preview
Huahui Health
Beijing, Beijing, Chinahuahuihealth.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Huahui Health has developed a robust pipeline of innovative therapies targeting liver diseases—especially hepatitis B and D—leveraging the discovery of NTCP as a viral entry receptor. Its lead asset, Libevitug (HH‑003), an anti-preS1 human monoclonal antibody, received FDA Breakthrough Therapy Designation for chronic HDV. The company also develops candidates for solid tumors using advanced antibody engineering. Early clinical results show promise in achieving functional cures for hepatitis B/D with ongoing trials in China and globally.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- monoclonal antibodies (mAbs)small moleculesantibody drug conjugates (ADCs)biological products
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
Beyond the preview
Go deeper on Huahui Health.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Huahui Health.